Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Mallinckrodt
Cantor Fitzgerald
Chinese Patent Office
Healthtrust
Cerilliant
UBS
AstraZeneca
Fish and Richardson

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent RE39593 protect, and when does it expire?


Patent ► Subscribe protects NUCYNTA and NUCYNTA ER and is included in three NDAs. There have been zero Paragraph IV challenges on Nucynta and Nucynta ER

This patent has thirty-seven patent family members in twenty-six countries.

Summary for Patent: ► Subscribe

Title:1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Abstract:1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I ##STR00001## a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.
Inventor(s): Buschmann; Helmut (Esplugues de Llobregat, ES), Strassburger; Wolfgang (Wuerselen, DE), Friderichs; Elmar (Stolberg, DE)
Assignee: Gruenenthal GmbH (Aachen, DE)
Application Number:10/462,844
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-001Nov 20, 2008RXYesNo► Subscribe► SubscribeYY RELIEF OF MODERATE TO SEVERE ACUTE PAIN
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-002Nov 20, 2008RXYesNo► Subscribe► SubscribeYY RELIEF OF MODERATE TO SEVERE ACUTE PAIN
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-003Nov 20, 2008RXYesYes► Subscribe► SubscribeYY RELIEF OF MODERATE TO SEVERE ACUTE PAIN
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-001Aug 25, 2011RXYesNo► Subscribe► SubscribeYY RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
Depomed Inc
NUCYNTA ER
tapentadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL200533-001Aug 25, 2011RXYesNo► Subscribe► SubscribeYY MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany44 26 245Jul 23, 1994

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,248,737 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects► Subscribe
6,344,558 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2154424► Subscribe
China1125221► Subscribe
China1077566► Subscribe
Colombia4410179► Subscribe
Czech Republic9501904► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
US Department of Justice
Julphar
Cantor Fitzgerald
Merck
Covington
QuintilesIMS
Chubb
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot